Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
What to know about rare B-cell malignancies in 2025.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Journal: Lancet (London, England)
Published: July 23, 2024
Morvan Fibrillary Chorea Associated with Monoclonal B Cell Lymphocytosis.
Journal: The American journal of case reports
Published: July 04, 2024
Heterogeneous Presentations of iMCD: A Single-Institution Case Series.
Journal: Case reports in hematology
Published: June 14, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
Journal: Blood cancer journal
Published: May 14, 2024
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Journal: European journal of haematology
Published: August 04, 2023
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 18, 2023
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 20, 2023
Last Updated: 09/26/2026